ATLANTA--(BUSINESS WIRE)--June 6, 2006--Biogen Idec Inc. (Nasdaq:BIIB - News) and Schering AG, Germany (FSE:SCH) (NYSE:SHR - News) announced new data presented this week at the 42nd American Society of Clinical Oncology (ASCO) Annual Meeting in Atlanta, Ga., showing that lymphoma patients with refractory and hard-to-treat disease -- specifically mantle cell lymphoma (MCL), follicular non-Hodgkin’s lymphoma (NHL) and primary central nervous system (CNS) lymphoma -- experienced improved response and remission rates following administration of ZEVALIN® (Ibritumomab Tiuxetan) radioimmunotherapy as consolidation treatment after other, more standard therapies have been given. Additionally, data suggest the use of ZEVALIN as a component of a transplant regimen may reduce patients’ risk of relapse.
